Eli Lilly’s Alimta approvad for lung cancer
First-line chemotherapy regimen showed clinically relevant survival differences in specific histology types of advanced non-small cell lung cancer. – Eli Lilly and Company (NYSE: LLY) announced that it received approval from the U.S. Food and Drug Administration (FDA) for the use of ALIMTA(R) (pemetrexed for injection), in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer (NSCLC), for patients with nonsquamous histology.